A gliclazid használata a differenciált szulfanilureaalkalmazás tükrében

Translated title of the contribution: The use of gliclazide in the mirror of the individualized sulfonylurea therapy

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In addition to the common blood glucose lowering effect, sulfonylurea compounds are different in many aspects from each other. Based on earlier findings the second generation gliclazide has special advantages within this group. Although the number of experimental and clinical observations on gliclazide is continuously increasing, these novel findings are not in the focus anymore due to the appearance of new antidiabetics. The article overviews recent experimental (receptorial effect, the absence of Epac2 activation, antioxidant properties, possible incentive of factors participating in beta-cell differentiation) and pharmacogenomic data, and compares them with clinical observations obtained from gliclazide treatment (hypoglycaemias, parameters of cardiovascular outcome). The data underline the advantages of gliclazide, the highly pancreas-selective nature, preservation of the ischemic precondition, favourable hemodynamic properties and potential reduction of the beta-cell loss as compared to other compounds of the group. However, gliclazide is not free from disadvantages characteristic to sulfonylureas in general (blood glucose independent insulin stimulation, beta-cell depletion). Comparing gliclazide with other derivatives of the group, the above data indicate individual benefits for the application when sulfonylurea compound is the drug of choice. Orv. Hetil., 2014, 155(14), 541-548.

Original languageHungarian
Pages (from-to)541-548
Number of pages8
JournalOrvosi Hetilap
Volume155
Issue number14
DOIs
Publication statusPublished - Apr 1 2014

Fingerprint

Gliclazide
Sulfonylurea Compounds
Blood Glucose
Therapeutics
Pharmacogenetics
Hypoglycemic Agents
Motivation
Cell Differentiation
Pancreas
Antioxidants
Hemodynamics
Insulin
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A gliclazid használata a differenciált szulfanilureaalkalmazás tükrében. / Winkler, G.

In: Orvosi Hetilap, Vol. 155, No. 14, 01.04.2014, p. 541-548.

Research output: Contribution to journalArticle

@article{2a31ec53d8c3485ba6811189951b8d6a,
title = "A gliclazid haszn{\'a}lata a differenci{\'a}lt szulfanilureaalkalmaz{\'a}s t{\"u}kr{\'e}ben",
abstract = "In addition to the common blood glucose lowering effect, sulfonylurea compounds are different in many aspects from each other. Based on earlier findings the second generation gliclazide has special advantages within this group. Although the number of experimental and clinical observations on gliclazide is continuously increasing, these novel findings are not in the focus anymore due to the appearance of new antidiabetics. The article overviews recent experimental (receptorial effect, the absence of Epac2 activation, antioxidant properties, possible incentive of factors participating in beta-cell differentiation) and pharmacogenomic data, and compares them with clinical observations obtained from gliclazide treatment (hypoglycaemias, parameters of cardiovascular outcome). The data underline the advantages of gliclazide, the highly pancreas-selective nature, preservation of the ischemic precondition, favourable hemodynamic properties and potential reduction of the beta-cell loss as compared to other compounds of the group. However, gliclazide is not free from disadvantages characteristic to sulfonylureas in general (blood glucose independent insulin stimulation, beta-cell depletion). Comparing gliclazide with other derivatives of the group, the above data indicate individual benefits for the application when sulfonylurea compound is the drug of choice. Orv. Hetil., 2014, 155(14), 541-548.",
keywords = "antioxidant behaviour, beta-cell mass, Epac2, hypoglycemia, pharmacogenomics, sulfonylurea receptor",
author = "G. Winkler",
year = "2014",
month = "4",
day = "1",
doi = "10.1556/OH.2014.29850",
language = "Hungarian",
volume = "155",
pages = "541--548",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "14",

}

TY - JOUR

T1 - A gliclazid használata a differenciált szulfanilureaalkalmazás tükrében

AU - Winkler, G.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - In addition to the common blood glucose lowering effect, sulfonylurea compounds are different in many aspects from each other. Based on earlier findings the second generation gliclazide has special advantages within this group. Although the number of experimental and clinical observations on gliclazide is continuously increasing, these novel findings are not in the focus anymore due to the appearance of new antidiabetics. The article overviews recent experimental (receptorial effect, the absence of Epac2 activation, antioxidant properties, possible incentive of factors participating in beta-cell differentiation) and pharmacogenomic data, and compares them with clinical observations obtained from gliclazide treatment (hypoglycaemias, parameters of cardiovascular outcome). The data underline the advantages of gliclazide, the highly pancreas-selective nature, preservation of the ischemic precondition, favourable hemodynamic properties and potential reduction of the beta-cell loss as compared to other compounds of the group. However, gliclazide is not free from disadvantages characteristic to sulfonylureas in general (blood glucose independent insulin stimulation, beta-cell depletion). Comparing gliclazide with other derivatives of the group, the above data indicate individual benefits for the application when sulfonylurea compound is the drug of choice. Orv. Hetil., 2014, 155(14), 541-548.

AB - In addition to the common blood glucose lowering effect, sulfonylurea compounds are different in many aspects from each other. Based on earlier findings the second generation gliclazide has special advantages within this group. Although the number of experimental and clinical observations on gliclazide is continuously increasing, these novel findings are not in the focus anymore due to the appearance of new antidiabetics. The article overviews recent experimental (receptorial effect, the absence of Epac2 activation, antioxidant properties, possible incentive of factors participating in beta-cell differentiation) and pharmacogenomic data, and compares them with clinical observations obtained from gliclazide treatment (hypoglycaemias, parameters of cardiovascular outcome). The data underline the advantages of gliclazide, the highly pancreas-selective nature, preservation of the ischemic precondition, favourable hemodynamic properties and potential reduction of the beta-cell loss as compared to other compounds of the group. However, gliclazide is not free from disadvantages characteristic to sulfonylureas in general (blood glucose independent insulin stimulation, beta-cell depletion). Comparing gliclazide with other derivatives of the group, the above data indicate individual benefits for the application when sulfonylurea compound is the drug of choice. Orv. Hetil., 2014, 155(14), 541-548.

KW - antioxidant behaviour

KW - beta-cell mass

KW - Epac2

KW - hypoglycemia

KW - pharmacogenomics

KW - sulfonylurea receptor

UR - http://www.scopus.com/inward/record.url?scp=84897489466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897489466&partnerID=8YFLogxK

U2 - 10.1556/OH.2014.29850

DO - 10.1556/OH.2014.29850

M3 - Article

C2 - 24681676

AN - SCOPUS:84897489466

VL - 155

SP - 541

EP - 548

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 14

ER -